Cantor Fitzgerald analyst Elemer Piros raised his price target for Aurinia Pharmaceuticals to $24 from $18 and reiterates an Overweight rating on the shares following the company's Q4 results. The new target reflects Aurinia's recent Notice of Allowance regarding a U.S. patent related to voclosporin's method of use. The analyst no longer anticipate a decrease in the voclosporin price in 2027 from generic entry. However, the largest driver of Aurinia's shares will likely be a focus on Phase 3 data for voclosporin for the treatment of lupus nephritis, which could be announced by year-end 2019, says Piros.